Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease

British Journal of Dermatology

Volumn 161, Issue 2, 2009, Pages 357-363

  Chen, S ^a,b   Nakahara, T ^a   Uchi, H ^a   Takeuchi, S ^a   Takahara, M ^a   Kido, M ^a   Dugu, L ^a   Tu, Y ^b   Moroi, Y ^a   Furue, M ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

AKT; CDK2; Extramammary Paget's disease; MTOR

Indexed keywords

CDK2 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 2; EIF4EBP1 PROTEIN, HUMAN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOPROTEIN; PROTEIN KINASE; PROTEIN KINASE B; S6 KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ARTICLE; CELL PROLIFERATION; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; PAGET SKIN DISEASE; SKIN TUMOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PAGET DISEASE EXTRAMAMMARY; PHOSPHOPROTEINS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SKIN NEOPLASMS;

EID: 73349118143     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09179.x     Document Type: Article

References (50)

1. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
2. Dufner A, Andjelkovic M, Burgering BM et al. Protein kinase localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation. Mol Cell Biol 1999; 19:4525-34.
3. Tee AR, Blenis J. mTOR, translational control and human disease. Semin Cell Dev Biol 2004; 16:29-37.
4. Majewski M, Korecka M, Joergensen J et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft protecting doses. Transplantation 2003; 75:1710-17.
5. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol 2004; 15:171-6.
6. Fang X, Yu SX, Lu Y et al. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A2000; 97:11960-5.
7. Sakamoto K, Hirshman MF, Aschenbach WG et al. Contraction regulation of Akt in rat skeletal muscle. J Biol Chem 2002; 277:11910-17.
8. Roux PP, Ballif BA, Anjum R et al. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A 2004; 101:13489-94.
9. Shaw RJ, Bardeesy N, Manning BD et al. The LKβ1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004; 6:91-9.
10. Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 1999; 253:100-9.
11. Ferrari S, Bandi HR, Hofsteenge J et al. Mitogen activated 70K S6 kinase. Identification of in vitro 40S ribosomal S6 phosphorylation sites. J Biol Chem 1991; 266:22770-5.
12. Flotow H, Thomas G. Substrate recognition determinants of the mitogen-activated 70K S6 kinase from rat liver. J Biol Chem 1992; 267:3074-8.
13. Sarbassov DD, Sabatini DM. Redox regulation of the nutrientsensitive raptor-mTOR pathway and complex. J Biol Chem 2005; 280:39505-9.
14. Peng T, Golub TR, Sabatini DM. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol 2002; 22:5575-84.
15. Sakata A, Kuwahara K, Ohmura T et al. Involvement of a rapamycin-sensitive pathway in CD40-mediated activation of murine B cells in vitro. Immunol Lett 1999; 68:301-9.
16. Takano A, Usui I, Haruta T et al. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol Cell Biol 2001; 21:5050-62.
17. Ozes ON, Akca H, Mayo LD et al. A phosphatidylinositol 3-kinase/ akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci U S A 2001; 98:4640-5.
18. Majewski M, Korecka M, Kossev P. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A 2000; 97:4285-90.
19. Nepomuceno RR, Balatoni CE, Natkunam Y et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein-Barr virus B-cell lymphomas. Cancer Res 2003; 63:4472-80.
20. Easton JB, Houghton PJ. Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets 2004; 8:551-64.
21. Rowinsky EK. Targeting the molecular target of repaying (mTOR). Curr Opin Oncol 2004; 16:564-75.
22. Vignot S, Faivre S, Aguirre D et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 4:525-37.
23. Yu K, Toral-Barza L, Discafani C et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8:249-58.
24. Colozza M, Azambuja E, Cardoso F et al. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005; 16:1723-39.
25. Keyomarsi K, Tucker SL, Buchholz TA et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347:1566-75.
26. Kuhling H, Alm P, Olsson H et al. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J Pathol 2003; 199:424-31.
27. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 1997; 13:261-91.
28. Liu H, Moroi Y, Yasumoto S et al. Expression of insulin-like growth factor-1 receptor, p-AKT and p-ERK1/2 protein in extramammary Paget's disease. Br J Dermatol 2006; 155:586-91.
29. Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer 2003; 3:179-92.
30. Vogt PK. PI 3-kinase, mTOR, protein synthesis and cancer. Trends Mol Med 2001; 7:482-4.
31. Fresno Vara JA, Casado E, de Castro J et al. PI3K/Akt signaling pathway and cancer. Cancer Treat Rev 2004; 30:193-204.
32. Fry MJ. Phosphoinositide 3-kinase signaling in breast cancer: how big a role might it play? Breast Cancer Res 2001; 3:304-12.
33. Hu Q, Klippel A, Muslin AJ et al. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 1995; 268:100-2.
34. Lee AV, Yee D. Insulin-like growth factors and breast cancer. Biomed Pharmacother 1995; 49:415-21.
35. Scheid MP, Woodgett JR. Phosphatidylinositol 3′ kinase signaling in mammary tumorigenesis. J Mammary Gland Biol Neoplasia 2001; 6:83-99.
36. Hankinson SE, Willett WC, Colditz GA et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351:1393-6.
37. Smith GD, Gunnell D, Holly J. Cancer and insulin-like growth factor-I. A potential mechanism linking the environment with cancer risk. BMJ 2000; 321:847-8.
38. Pollack M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 2000; 36:1224-8.
39. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92:1472-89.
40. Resnicoff M, Baserga R. The role of the insulin-like growth factor-I receptor in transformation and apoptosis. Ann NY Acad Sci 1998; 842:76-81.
41. Berretta L, Gingras AC, Svitkin YV et al. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 1996; 15:658-64.
42. Graves LM, Bornfeldt KE, Argast GM et al. c-AMP-and rapamycinsensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells. Proc Natl Acad Sci U S A 1995; 92:7222-6.
43. Lin TA, Kong X, Saltiel AR et al. Control of PHAS-I by insulin in 3T3-L1 adipocytes. Synthesis, degradation, and phosphorylation by a rapamycin-sensitive and mitogen-activated protein kinaseindependent pathway. J Biol Chem 1995; 270:18531-8.
44. Dilling BD, Germain GS, Dudkin L et al. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 2002; 277:13907-17.
45. Castellvi J, Garcia A, Rojo F et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006; 107:1801-11.
46. Rojo F, Najera L, Lirola J et al. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 2007; 13:81-9.
47. Wendel HG, De Stanchina E, Fridman JS et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428:332-7.
48. Kourea HP, Koutras AK, Scopa CD et al. Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma. J Clin Pathol 2003; 56:328-35.
49. Maddika S, Ande SR, Wiechec E et al. Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. J Cell Sci 2008; 121:979-88.
50. Kim SJ, Nakayama S, Miyoshi Y et al. Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. Ann Oncol 2008; 19:68-72.